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The efficacy of small-molecule kinase inhibitors has
recently changed standard clinical practice for several
solid cancers. Glioblastoma is a solid cancer that univer-
sally recurs and unrelentingly results in death despite
maximal surgery and radiotherapy with concomitant
and adjuvant temozolomide. Several clinical studies
using kinase inhibitors in glioblastoma have been
reported. The present study systematically reviews the
efficacy, toxicity, and tissue analysis of small-molecule
kinase inhibitors in adult patients with glioblastoma as
reported in published clinical studies and determines
which kinases have been targeted by the inhibitors
used in these studies. Publications were retrieved using
a MEDLINE search and by screening meeting abstracts.
A total of 60 studies qualified for inclusion, of which
25 were original reports. A total of 2385 glioblastoma
patients receiving kinase inhibitors could be evaluated.
The study designs included 2 phase III studies and 37
phase II studies. Extracted data included radiological
response, progression-free survival, overall survival, tox-
icity, and biomarker analysis. The main findings were
that (i) efficacy of small-molecule kinase inhibitors in
clinical studies with glioblastoma patients does not yet
warrant a change in standard clinical practice and (ii)
6 main kinase targets for inhibitors have been evaluated
in these studies: EGFR, mTOR, KDR, FLT1, PKCb, and
PDGFR.
Keywords: clinical trial, glioblastoma, kinases, review,
small-molecule inhibitors.
S
mall-molecule compounds that inhibit the kinase
domain of specific kinase targets have recently
changed clinical practice for several advanced
solid cancers, such as lapatinib, which inhibits HER2
and EGFR in HER2-positive metastatic breast cancer;1
sunitinib, which inhibits VEGFR and PDGFR in meta-
static renal-cell carcinoma;2 and sorafenib, which
inhibits RAF, PDGFR, VEGFR, and KIT in advanced
hepatocellular carcinoma3 and also in advanced renal-
cell carcinoma.4 These advances followed the seminal
contribution to cancer therapy by gefitinib for chronic
myeloid leukemia by inhibiting the ABL/CBR fusion
protein5 and for gastrointestinal stroma tumor by
inhibition of the activating KIT mutation.6
Glioblastoma is one of the most aggressive solid
cancers and the most common primary brain tumor.
Because this tumor is inherently resistant to conventional
therapy, the median patient survival is approximately 14
months. Although standard treatment with surgery,
irradiation, and temozolomide postpones progression
and extends survival to some extent, these tumors univer-
sally recur and unrelentingly result in death.7 Therefore,
improvement of treatment options for patients with glio-
blastoma is imperative. For this purpose, inhibition of
kinase targets that drive glioblastoma growth seems a
reasonable treatment strategy to be further explored.
Several clinical studies have reported the efficacy of
kinase inhibitors in glioblastoma. The outcome of
these clinical studies has not been systematically
reviewed, although a number of reviews highlight in
their discussions a selection of studies using kinase
inhibitors for glioblastoma.8–15 The aim of the present
study was to review the efficacy of small-molecule
kinase inhibitors in adult patients with glioblastoma
based on published clinical study results and to deter-
mine which kinases are targeted by the inhibitors used
in these clinical studies.
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Search Strategy and Data Extraction
Results of clinical studies were obtained from 2 sources.
A systematic search was performed in PubMed
MEDLINE with the MeSH term “glioma” limited by
publication type “clinical trial” and “adults”, with pub-
lication after January 1, 2002. Furthermore, the
abstracts of the annual meetings of the American
Society for Clinical Oncology from 2002 to 2008, of
the European Association of Neuro-Oncology from
2005 to 2008, of the Society for Neuro-Oncology from
2003 to 2008, and of the World Federation of
Neuro-Oncology in 2001 and 2005 were systematically
searched for preliminary outcome data of clinical
studies.
To compare the data obtained from studies without
control patient groups, the results from published
studies in patients with newly diagnosed and progressive
glioblastoma receiving conventional therapy were
included as historical controls.
The data extracted from these sources were the total
number of patients in the study, the number of evaluated
patients in the population used for data extraction,
histopathological diagnosis, study design, type of
inhibitor and dosage, inhibitor target, percentage of
radiologically complete responses and partial responses,
median progression-free survival (mPFS), PFS at 6
months (PFS6), median overall survival (mOS), OS at
12 months (OS12), the number of adverse events of
grade 3, 4, or 5 according to the National Cancer
Institute Common Toxicity Criteria, and the tissue
analysis in relation to response. Data on the effect of
kinase inhibitors on the functional status of patients
were unavailable from the vast majority of evaluable
studies. As far as possible, the data were extracted for
the glioblastoma subgroup. When exact percentages
and survival times were not provided, these were esti-
mated from the time to progression and survival curves.
Publications and abstracts were screened for efficacy
data. Audiovisual material at the ASCO website (http://
www.asco.org/ASCOv2/Meetings/Abstracts) was
available for some of the meeting presentations and
was scanned for additional data not included in the
meeting abstract. If no outcome data (ie, radiological
response, PFS, or OS) were provided, the publication
or abstract was excluded from the analysis.
Meta-analysis of the efficacy data was not performed
because of the small sample sizes and the highly selected
populations with inhomogeneity of inclusion criteria,
histopathological diagnosis, stages of disease, drug sche-
dules, and definitions of outcome and efficacy.
Therefore, analysis of data is descriptive and qualitative.
Results
A total of 60 studies qualified for inclusion, of which 25
were published as original reports in peer-reviewed jour-
nals and 35 as meeting abstracts. Study designs included
2 phase III studies, 1 randomized phase II study, 28
single-arm phase II studies, 8 single-arm phase I/II
studies, 16 phase I studies, 4 retrospective observational
series, and 1 pharmacodynamic study. The sum of eval-
uated patients receiving kinase inhibitors was 2385. The
average number of evaluable patients per study was 40,
ranging from 6 to 178.
The efficacy, toxicity, and tissue analysis results are
listed in Table 1.
Radiological Response
Radiological response rates (ORs) were evaluable in 51
studies.
The reported objective radiological ORs were
approximately double the baseline rates after inhibition
of EGFR using erlotinib or gefitinib in 6 of 12 evaluable
single-inhibitor studies, in 2 of 7 studies combining inhi-
bition of EGFR and mTOR, and in none of 4 evaluable
studies combining EGFR inhibition with conventional
therapy. In 1 study combining EGFR inhibition by erlo-
tinib with VEGF inhibition by bevacizumab, an OR of
48% was observed,16 which was comparable with the
results for pan-VEGFR inhibition with cediranib.17
The ORs after inhibition of mTOR were comparable
with the baseline results in 4 single-agent studies.
Inhibition of PKCb by enzastaurin increased the OR
compared with baseline in 1 of 3 studies. Two of 6
single-agent studies using PDGFR/KIT/ABL inhibition
by imatinib and 3 of 5 combination therapy studies
with imatinib and hydroxyurea showed an increased
OR. The combination of imatinib, hydroxyurea, and
KDR inhibition by vatalanib resulted in increased ORs
in 2 of 2 studies.
Progression-Free Survival
The PFS was evaluable as mPFS in 36 studies and as
PFS6 in 34 studies.
The mPFS approximately doubled in progressive glio-
blastoma compared with baseline in 1 of 8 evaluable
studies with EGFR inhibition by gefitinib or erlotinib18
and in 1 of 6 evaluable studies with combined EGFR
and mTOR inhibition using gefitinib at high dose.19
Seven evaluable studies combining EGFR inhibition
with conventional therapy had PFS comparable with
baseline values. The mPFS was comparable with base-
line in 3 evaluable studies with single-agent mTOR inhi-
bition. The remarkable OR of VEGFR inhibition by
cediranib was substantiated by a slightly increased
mPFS of 4 months.17 The mPFS was increased in 2 of
4 evaluable studies with imatinib as single-agent
therapy, although a relevant number of anaplastic
gliomas were included in these 2 studies.20,21 One of 3
evaluable studies using combined imatinib and hydro-
xyurea showed a small increase in mPFS of 3.6 months
compared with baseline.22
The PFS6 was comparable with baseline in all 8 eva-
luable studies with EGFR inhibitors as single-agent
therapy, was possibly increased in 2 of 5 evaluable
studies with combined EGFR and mTOR inhibition
including 1 study with a number of anaplastic
De Witt Hamer: Kinase inhibitors in glioblastoma
NEURO-ONCOLOGY † M A R C H 2 0 1 0 305
 at Vrije Universiteit - Library on July 11, 2011
n
e
u
ro
-o
n
cology.oxfordjournals.org
D
ow
nloaded from
 
Table 1. A summary of efficacy, toxicity, and tissue analysis in clinical studies with small molecule kinase inhibitors in adult patients with newly diagnosed and progressive glioblastoma.
Kinase target First author Year Reference(s) Total
no. of
patients
in the
study
No. of patients in
evaluated population
Study
design
Therapy CR
(%)
PR
(%)
OR
(%)
mPFS PFS6
(%)
mOS OS12
(%)
Toxicity
as no. of
grade 3,
4, or 5
events in
no. of
evaluable
patients
Tissue analysis to
predict responsee
Newly
diagnosed
Progressive
GB AG GB AG
Baseline studies
Stupp 2005 7 573 286 III rth — — — 5 9 12.1 51 — NA
Stupp 2005 7 573 287 III rth þ tmz — — — 6.9 27 14.6 61 75 in 284 NA
Athanassiou 2005 60 130 57 r II rth — — — 5.2 45 7.7 16 — NA
Athanassiou 2005 60 130 53 r II rth þ tmz — — — 10.8 67 13.4 56 6 in 110 NA
Brada 2001 61 138 138 II tmz 2 6 8 2.1 18 5.4 15 60 in 138 NA
Yung 2000 62 225 112 r II tmz 0 5 5 3 21 7.1 22 26 in 110 NA
Yung 2000 62 225 113 r II Procarbazine 0 5 5 2.1 8 5.6 18 26 in 110 NA
Wong 1999 63 375 225 d Various salvage treatments
without tmz,
without kinase inhibitors
— — 6 2.3 15 6.3 21 — NA
Single target small molecule inhibitors
EGFR
Van den Bent 2009 45,64,65 54 54 r II Erlotinib 150–500 mg pod vs
tmz or carmustine
0 4 4 1.8 11 7.7 22 13 in 54 ihc: EGFR EGFRvIII* PTEN
pAKT; fish: EGFR; mut: EGFR
Preusser 2008 44 21 14 7 RObs Erlotinib 100–150 mg pod or
Gefitinib 250 mg pod
0 14 14 3.1 19 5.1 5 1 in 21 ihc: EGFR EGFRvIII PTEN
pAKT
Franceschi 2007 42 16 16 II Gefitinib 250 mg pod 0 0 0 2.1 13 6.2 14 5 in 28 ihc: EGFR pAKT; fish: EGFR
Buie 2007 66 6 6 I Erlotinib 450–900 mg every 3
days
0 17 17 — — — — 0 in 6 None
Mellinghoff 2006 46 49 49 II Erlotinib 150–500 mg pod or
Gefitinib 250–1000 mg pod
0 18a 18 — — — — — ihc: EGFRvIII* PTEN*; fish:
EGFR; mut: EGFR, HER2,
PTEN; pcr: EGFR EGFRvIII
Haas-Kogan 2005 43 52 29 I Erlotinib dosage unavailable 0 17 17 — — — — — ihc: EGFR* EGFRvIII pAKT*;
fish: EGFR*; mut: EGFR PTEN
Cloughesy 2005 67,68 48 48 II Erlotinib 150–300 mg pod 2 6 8 — 17 — — — ihc: EGFR EGFRvIII PTEN;
fish: EGFR
Rich 2004 31,69 57 57 II Gefitinib 500–1000 mg pod 0 0 0 2 13 9.9 36 27 in 55 ihc: EGFR EHGRvIII; pcr:
EGFR
Uhm 2004 70 96 96 II Gefitinib 500–1000 mg pod — — — 6.8 62 12.8 54 21 in 63 ihc: EGFR EGFRvIII; fish:
EGFR
Raizer 2004 71 45 31 II Erlotinib 150 mg pod 0 0 0 2.3 0 — — — None
Lieberman 2004 72 65 38 I/II Gefitinib 250–1000 mg pod 0 13 13 2 9 — — — None
Vogelbaum 2004 18,73,74 31 16 II Erlotinib 150 mg pod 0 25 25 5.2 — — — — fish: EGFR
Peery 2003 75 57 52 II Gefitinib 500–1000 mg pod 0 2 2 — — — — 10 in 52 ihc: EGFR EGFRvIII; pcr: EGFR
mTOR
Cloughesy 2008 39 15 15 I Rapamycin 2–10 mg pod 0 7 7 3.6 — — — 7 in 15 ihc: pS6K pAKT pPRAS40*
Galanis 2005 27 65 65 II Temsirolimus 250 mg ivw 0 0 0 2.3 8 4.4 — 40 in 65 ihc: PTEN S6K pS6K* AKT
pAKT; fish: EGFR PTEN; act:
S6K
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Chang 2005 26,76 43 43 II Temsirolimus 170–250 mg
ivw
0 5 5 2.3 2 — — 49 in 43 None
Chang 2004 77 12 9 I Temsirolimus 250–330 mg
ivw
0 0 0 — — — — 4 in 12 None
VEGFR
FLT1/KDR Batchelor 2007 17 16 16 II Cediranib 45 mg pod 0 56 56 4 30 7.5 — 9 in 16 ihc: VEGFR1 VEGFR2
VEGFR3 PDGFRa PDGFRb;
plasma: VEGF PIGF*
sVEGFR2* bFGF* SDF1a*
KDR Conrad 2004 28,78–80 55 55 I/II Vatalanib 150–2000 mg pod 0 4 4 2.5 25 — — 10 in 45 None
PKCb
Kreisl 2009 81 26 17 9 I Enzastaurine 500–1000 mg
pod
4 4 8 1.4 — 5.7 — 9 in 22 Plasma: Pgsk3b
Fine 2008 34,82–84 266 174 III Enzastaurine 500 mg pod vs
lomustine
0 3 3 1.5 11 6.6 15 14 in 167 None
Fine 2005 85,86 85 57 II Enzastaurine 500 mg pod 0 18 18 — — — — 3 in 85 None
Multitarget small molecule inhibitors
PDGFR/KIT/ABL
Raymond 2008 87–89 112 51 II Imatinib 600–1000 mg pod 0 6 6 1.8 16 5.9 — 34 in 112 mut: KIT PDGFRa PDGFRb
ABCG2
Razis 2007 90 20 19 1 PD Imatinib 800 mg pod 0 0 0 — — 6.2 — — ihc: AKT MAPK p27 EGFR
PDGFR
Viola 2007 21 20 18 2 II Imatinib 800 mg pod 0 0 0 7.8 52 — — 0 in 20 ihc: PDGFRa PDGFRb
Wen 2006 41,91,92 55 34 I/II Imatinib 800 mg pod 0 6 6 — 3 — — 35 in 55 pcr: EGFR EGFRvIII; mut:
PTEN PDGFRa PDGFRb
Marosi 2006 20 34 23 11 II Imatinib 400 mg pod 0 18 18 9.5 33 12.3 45 0 in 34 ihc: PDGFRa PDGFRb KIT
ABL
Franceschi 2005 93 28 16 II Imatinib 250 mg pod 0 0 0 2 13 6.1 14 5 in 28 None
KIT/PDGFR/KDR/FLT3/RET
Chaskis 2008 94 12 7 5b II Sunitinib 37.5 mg pod 0 8 8 — — — — 5 in 12 None
EGFR/VEGFR
Kreisl 2008 95 32 32 II Vandetanib 300 mg pod 0 16 16 — — — — 11 in 32 None
KDR/FLT1/PDGFR/FLT3/RET/KIT
Reardon 2008 96 16 16 II Sorafenib 400 mg pod þ tmz 0 0 0 — — — — 7 in 16 None
Combination therapy
EGFR þ mTOR
Kreisl 2009 36 22 22 I/II Gefitinib 250 mg
pod þ everolimus 70 mg ivw
0 14 14 2.6 5 — — 21 in 22 ihc: EGFR PTEN pAKT pS6K
EGFRvIII
Friedman 2008 97 27 27 II Erlotinib 150–500 mg
pod þ Rapamycin 5–10 mg
pod
0 0 0 — — — — 6 in 27 None
Phuphanich 2008 19 18 18 I Gefitinib 250–1000 mg
pod þ rapamycin 2–6 mg
pod
0 0 0 5 — 9.4 — 6 in 18 None
Reardon 2006 24 34 29 5 I Gefitinib 500–750 mg
pod þ rapamycin 5–10 mg
pod
0 6 6 2.1 24 — — 36 in 32 ihc: pMAPK pS6K pAKT
PTEN EGFR; fish: EGFR PTEN
Continued
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Table 1. Continued
Kinase target First author Year Reference(s) Total
no. of
patients
in the
study
No. of patients in
evaluated population
Study
design
Therapy CR
(%)
PR
(%)
OR
(%)
mPFS PFS6
(%)
mOS OS12
(%)
Toxicity
as no. of
grade 3,
4, or 5
events in
no. of
evaluable
patients
Tissue analysis to
predict responsee
Newly
diagnosed
Progressive
GB AG GB AG
Doherty 2006 23 28 22 RObs Gefitinib 500 mg
pod þ rapamycin 4 mg pod
0 18 18 3 25 — — 3 in 28 None
Badruddoja 2006 98 21 18 I/II Gefitinib 500–1500 mg
pod þ rapamycin 2 mg pod
0 0 0 3 17 — — 8 in 18 None
Nguyen 2006 99 19 19 I/II Gefitinib 250 mg
pod þ everolimus 30–70 mg
ivw
0 11 11 2.6 5 6.5 — — None
EGFR þ conventional therapy
Prados 2009 32,100 65 65 II Erlotinib 100–300 mg
pod þ tmz
— — — 8.2 72 19.3 68 48 in 65 ihc: EGFR EGFRvIII PTEN*;
fish: EGFR; pcr: MGMT*
Schwer 2009 25 15 11 4 I Gefitinib 250 mg
pod þ radiosurgery
— — — — 53 10 — — None
Brown 2008 101 97 97 II Erlotinib 150 mg podþ
tmz þ rth
— — — 7.2 — 15.3 61 — ihc: EGFR EGFRvIII PTEN
p53; fish: EGFR
De Groot 2008 37,102 44 43 II Erlotinib 150–200 mg
pod þ carboplatin
0 2 2 2 13 7.5 — 82 in 43 ihc: EGFR EGFRvIII pAKT
PTEN
Chakravarti 2006 103–106 178 178 I/II Gefitinib 500 mg pod þ rth — — — 5.1 — 11 — — ihc: EGFRvIII PTEN
Prados 2006 107,108 83 60 I Erlotinib 100–500 mg
pod þ tmz
0 8 8 2 7 — — 36 in 83 None
Krishnan 2006 109 19 19 I Erlotinib 100–200 mg
pod þ rth
0 0 0 6 — 13.8 — 5 in 20 None
Brewer 2006 33,38,110 28 28 II Erlotinib 50–150 mg
pod þ tmz þ rth
0 0 0 3.6 — — — 40 in 27 Fish: EGFR
PDGFR/KIT/ABL þ hydroxyurea
Shah 2007 33 16 11 5 RObs Imatinib 400–500 mg
pod þ hydroxyurea
0 21 21 — — 10 — 8 in 16 None
Dresemann 2008 111,112 240 120 III Imatinib 600 mg
pod þ hydroxyurea vs
hydroxyurea
0 2 2 1.6 5 — — — None
Dresemann 2008 35,113 30 30 II Imatinib 600 mg
pod þ hydroxyurea
0 13 13 — 60 — 67 4 in 30 None
Dresemann 2006 29 30 30 RObs Imatinib 400–600 mg
pod þ hydroxyurea
3 17 20 2.5 32 4.8 25 0 in 30 None
Reardon 2005 22,114–116 33 33 II Imatinib 400–500 mg
pod þ hydroxyurea
3 6 9 3.6 27 12.2 — 14 in 33 None
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Others
KDR þ PDGFR/KIT/
ABL
Kirkpatrick 2008 30 37 34 3 I Vatalanib 2000 mg
pod þ imatinib ’standard
dose’ þ hydroxyurea
0 22 22 — 27 — — — None
EGFR þ VEGF Sathornsumetee 2008 16,117,118 25 25 II Erlotinib 200–650 mg
pod þ bevacizumab
— — 48 — 24 — — — None
EGFR þ SRC Reardon 2008 119 15 13 2 I Erlotinib 150–450 mg
pod þ dasatinib 100 mg pod
0 0 0 — — — — 1 in 15 None
KIT/PDGFR/KDR/
FLT/RET
Wuthrick 2008 120 10 10 I Sunitinib 37.5 mg pod þ rth 0 10 10 — — — — 1 in 10 None
KDR þ PDGFR/KIT/
ABL
Sathornsumetee 2007 121 35 35 I Vatalanib 500–1000 mg
pod þ imatinib 400–500 mg
pod þ hydroxyurea
0 29 29 — — — — 4 in 35 None
KDR/FLT1/
PDGFR þ EGFR/
HER2
Reardon 2007 122 32 32 II Pazopanib 400 mg
pod þ lapatinib 1000 mg pod
0 0 0 — — — — 10 in 75 ihc: PTEN EGFRvIII
PDGFR/KIT/ABL Sathornsumetee 2006 123 56 46 10c I Imatinib unavailable
dose þ tmz
0 7 7 — — — — 5 in 56 None
PDGFR/KIT/
ABL þ mTOR
Desjardins 2006 124 28 28 I Imatinib 400 mg
pod þ hydroxyurea þ
everolimus 2.5 mg ivd
0 4 4 — — — — 1 in 5 None
KDR Reardon 2004 125,126 60 60 I/II Vatalanib 500–1500 mg
pod þ tmz or lomustine
0 7 7 3.5 15 — — 3 in 60 None
Abbreviations: rII, randomized phase II study; Robs, retrospective observational study; PD:, pharmacodynamic study; tmz, temozolomide 150–200 mg/m2 po 5 days/28 days; rth, radiotherapy;
pod, per os daily; ivw, intravenous weekly; ivd, intravenous daily; CR, complete response; PR, partial response; mPFS, median progression-free survival; PFS6: progression-free survival at 6
months; mOS, median overall survival; OS12, overall survival at 12 months; ihc, immunohistochemistry to determine protein expression; fish, fluorescence in situ hybridization to determine gene
amplification; mut, sequencing analysis to determine gene mutation; pcr, PCR to determine gene copy number or gene expression; act, kinase activity assay to determine protein activity; plasma,
plasma protein concentration analysis; na, not applicable. For comparison, baseline studies with conventional therapies are listed. Studies are categorized by single-target inhibitors, multitarget
inhibitors, and combination therapies; subcategorized by kinase drug target; and sorted by year of publication and number of patients.
aPartial response defined as . 25% decrease of bidirectional area.
bIncluding 4 progressive low-grade gliomas.
cIncluding 1 pleiomorph xanthoastrocytoma.
dPrognosis study with data from 8 phase II trials.
eTissue analysis results that are significantly correlated with efficacy are marked with an asterisk.
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gliomas,23,24 and was increased in 1 of 4 evaluable
studies with EGFR inhibition combined with conven-
tional therapy, which included a relevant number of ana-
plastic gliomas.25 When EGFR inhibition was combined
with VEGFR ligand binding by bevacuzimab, the PFS6
was 24%.16 The PFS6 was comparable with baseline
using both evaluable single-agent mTOR inhibitors.26,27
In both studies with single-agent VEGFR inhibitors, the
PFS6 was increased, including a PFS6 of 30% after cedir-
anib in concordance with the increased OR and
mPFS.17,28 The PFS6 was comparable with baseline in
1 evaluable study with PKCb inhibition. The same 2
studies with single-agent imatinib that had an increased
mPFS also had an increase in PFS6.20,21 Again, the
number of anaplastic gliomas included in the study
populations likely contributed to this finding. A slight
increase in PFS6 was observed in 2 of 4 evaluable
studies with combination therapy using imatinib and
hydroxyurea, while 1 of these 2 studies was a retrospec-
tive observational series.22,29 Furthermore, the study
with combined imatinib, hydroxyurea, and KDR inhi-
bition by vatalanib had a PFS6 of 27%, although a
number of anaplastic gliomas were included.30
Overall Survival
The OS was evaluable as mOS in 23 studies and as OS12
in 12 studies.
The mOS increased to 9.9 months in 1 of 5 evaluable
studies with single-agent EGFR inhibition.31 In the 1
evaluable study with combined EGFR and mTOR inhi-
bition, the mOS was also increased.19 The mOS was
remarkably increased to 19.3 months in 1 of 6 evaluable
studies with the combination of EGFR inhibition and
conventional therapy, erlotinib, and temozolomide in
this study with newly diagnosed glioblastomas.32
Another study with combination therapy using EGFR
inhibition by gefitinib and radiosurgery showed an
increased mOS; however, anaplastic gliomas were
included.25 The one evaluable study with single-agent
mTOR inhibition had an mOS comparable with base-
line. The 1 evaluable study with VEGFR inhibition by
cediranib, with encouraging OR, mPFS, and PFS6,
barely presented an increase in mOS.17 The mOS was
comparable with baseline in 2 evaluable studies with
PKCb inhibition by enzastaurin. In 1 of 4 evaluable
studies with imatinib as single-agent therapy, the mOS
was increased, although a substantial number of ana-
plastic gliomas were included.20 The mOS was increased
in 2 of 3 evaluable studies with imatinib in combination
with hydroxyurea; of these 2 studies, 1 included a
number of anaplastic gliomas33 and the other showed
an mOS of 12.2 months in progressive glioblastoma.22
The OS12 was increased to 36% in 1 of 5 evaluable
studies with EGFR inhibition.26 In 1 of 2 evaluable
studies with EGFR inhibition by erlotinib combined
with temozolomide, the OS12 was increased to 68%.32
In 1 evaluable study with PKCb inhibition by enzas-
taurin, the OS12 was comparable with baseline.34 The
OS12 was increased to 45% in 1 of 2 evaluable studies
with imatinib as single-agent therapy, which included a
large number of anaplastic gliomas. Combination
therapy using imatinib and hydroxyurea increased the
OS12 in both evaluable studies.29,35
Toxicity
Toxicity data were evaluable in 26 studies.
The toxicity increased to 27 events in 55 patients in 1
of 7 evaluable studies with EGFR inhibition by gefitinib
compared with baseline.31 The toxicity of therapy com-
bining EGFR and mTOR inhibition was increased up to
36 events in 32 patients in 2 of 6 evaluable studies.24,36
Toxic events associated with therapy combining EGFR
inhibition by erlotinib with conventional therapy, such
as temozolomide,32 carboplatin,37 or temozolomide,
and radiotherapy38 were considerably increased, with
48 events in 65 patients, 82 in 43 patients, and 40 in
27 patients, respectively. In 3 of 4 evaluable studies
with mTOR inhibition by rapamycin or temsirolimus,
toxicity was increased up to 49 events in 43
patients.26,27,39 The toxicity was increased in 1 of 2
studies with VEGFR inhibition by cediranib17 and was
not increased with PKCb inhibition. Imatinib was
associated with increased toxicity (35 events in 55
patients) in 1 of 5 evaluable studies.40 The combination
therapy of imatinib and hydroxyurea showed increased
toxicity (up to 8 events in 16 patients) in 2 of 4 evaluable
studies.22,41
Tissue Analysis
Patient tissue was analyzed in relation to response in 27
studies. The activation status of a substrate downstream
of the kinase target was verified in 4 studies after EGFR
inhibition42–45 and in 2 studies after mTOR inhi-
bition,27,39 of which 3 provided an indication of target
inactivation after kinase inhibition.27,39,43 Several mol-
ecular markers have been found to predict response,
sometimes with conflicting results.
An association between tissue analysis and response
to EGFR inhibition was identified in 3 of 10 studies
that analyzed tissue. In one of these studies, the presence
of the EGFRvIII mutant correlated with poor PFS after
erlotinib.45 In the second study, the presence of the
EGFRvIII mutant coinciding with PTEN protein
expression was associated with radiological response
after erlotinib or gefitinib.46 In the third study, high
EGFR protein expression, EGFR amplification, and
low phosphorylated AKT protein expression, as a down-
stream target of EGFR, each correlated with radiological
response, and in addition, high phosphorylated AKT
protein expression was associated with poor PFS.43
A response correlation was found in 2 studies describ-
ing tissue analysis after mTOR inhibition. In one study,
high protein expression of phosphorylated PRAS40, as a
downstream target of AKT, correlated with poor PFS
after rapamycin.39 In the other study, high protein
expression of phosphorylated S6K, as a downstream
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target of mTOR, was associated with radiological
response after temsirolimus.27
After VEGFR inhibition by cediranib, radiological
tumor progression was associated with a decrease in
the plasma protein level of PIGF and an increase in
plasma protein levels of sVEGFR2, bFGF, and SDF1a.17
A survival benefit was identified in patients with both
a methylated MGMT promotor status and positive
PTEN protein expression after combination therapy of
EGFR inhibition by erlotinib and temozolomide during
and after radiotherapy.32
Kinase Drug Targets
The targets of small-molecule kinase inhibitors in clini-
cal studies with glioblastoma patients have mainly
been 6 kinases: EGFR, mTOR, KDR, FLT1, PKCb,
and PDGFR. In addition, 3 evaluated multitargeted
agents also inactivate other kinase targets nonspecifi-
cally: imatinib also inhibits KIT and ABL, sunitinib
also inhibits FLT3 and RET, and lapatinib also inhibits
HER2.
Discussion
The main findings of the present study are that (i) the
efficacy of small-molecule kinase inhibitors in clinical
studies with adult glioblastoma patients does not yet
warrant a change in standard clinical practice, and (ii)
the main kinase targets of the inhibitors evaluated in
these studies are EGFR, mTOR, KDR, FLT1, PKCb,
and PDGFR.
The evaluated studies have several limitations that
should be considered in interpreting these results. First,
many of the studies were not designed to determine the
efficacy of therapy and consequently no control group
was included for comparison of results in the interven-
tion group. Included in this analysis were outcome
results from 4 retrospective observational, 1 pharmaco-
dynamic, 16 phase I, and 8 phase I/II studies. Control
group data were available from 1 randomized phase II
and 2 phase III studies. Second, sample sizes were
small. For instance, the average number of patients in
the phase II studies was 39 (range: 12–65). Third, the
study populations predominantly consisted of patients
with progressive glioblastoma or anaplastic glioma,
except for 9 studies of patients with newly diagnosed
glioblastoma. Fourth, drug activity was usually
unknown, as the inactivation of downstream targets
was seldom verified in tissue samples. Fifth, the classical
study endpoints of radiological response, PFS, and OS
were evaluated, each with their limitations. Beneficial
effects for individual patients, for instance in terms of
improved quality of life or alleviation of symptoms,
cannot be excluded by evaluation of these classical end-
points. As an example of the limitations of the classical
endpoints, the radiological response criteria rely on
enhancement due to blood-brain barrier disruption.
Causes other than tumor progression can induce
enhancement, such as postoperative gliosis, infection,
or radiation necrosis, and enhancement can be reduced
by stabilization of the blood-brain barrier rather than
by a decrease of the tumor burden. Furthermore, limit-
ations to the PFS as an endpoint are inherent to the
radiological definition of progression, its dependence
on timing of radiological follow-up, and the fact that
radiological progression is not necessarily equal to cessa-
tion of clinical benefit. Evaluation of the OS is hampered
by bias from subsequent salvage therapies after the
trial intervention and does not reflect the quality of the
prolonged lifetime.
The lack of efficacy in these clinical studies can have
several causes. First, results that have been obtained in
preclinical glioma models and that have motivated
further clinical evaluation may not adequately represent
the pathobiology of glioblastoma in patients. Second,
the inhibitor may have failed to inactivate the target in
glioblastoma cells, for instance due to low concen-
trations in tumor tissue or agent inactivation mechan-
isms. Third, the pursued kinase target may be active
only in a subpopulation of patients. The efficacy of
kinase inhibition in this subpopulation may have been
diluted by unselected glioblastoma patients. Fourth,
alternative kinase signaling pathways may be active in
parallel with the inhibited target, so that a single
target’s inactivation does not reduce downstream onco-
genic signaling. Fifth, beneficial effects from these kinase
inhibitors are perhaps not portrayed by the classical end-
points as evaluated.
Several strategies may help overcome these issues.
First, the best kinase drug targets need to be identified
for glioblastoma. Second, the preclinical efficacy from
inhibition of these drug targets needs to be rigorously ver-
ified in several glioblastoma models to complement each
single model’s limitations. Third, kinase inhibitors need
to be developed and optimized further, for instance by
directing toward downstream targets or toward multiple
kinase targets or by using a combination of inhibitors.
However, the toxicity of the evaluated kinase inhibitors
was significant, and hence improved safety of new inhibi-
tors remains important. Fourth, the inactivation of the
target and its downstream substrate should be verified
in early studies with glioblastoma tissue obtained from
patients. An elegant proof-of-concept of this biological
activity endpoint was recently demonstrated.39 Fifth,
the study populations need to be enriched by including
patients likely to respond, by determining the activation
status of the aimed drug target. Sixth, other clinical trial
endpoints, such as quality of life and cognitive status, can
be considered in addition to the classical trial end-
points.47,48 The radiological response is a useful surro-
gate endpoint for glioma therapy in general, because
objective results are provided shortly after therapy.
From the presented data, it is clear that reduction in
enhancement can also be observed after kinase inhi-
bition. The PFS6 suitably predicts OS and therefore is
considered a meaningful endpoint for evaluation of pro-
gressive glioblastoma. Perhaps the ideal endpoint for
assessment of clinical benefit by targeted therapy would
be a multidimensional construct of imaging, symptoms,
quality, progression, and survival.
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Amore fundamental question iswhether glioblastoma
is in fact a kinase-driven cancer. Undoubtedly, oncogenic
kinase signaling is involved in glioblastoma, but whether
kinases are crucial for the oncogenic signaling network of
glioblastoma and are thereby amenable to therapeutic
inhibition, remains to be determined. Kinase drug
targets that have changed clinical practice in the treat-
ment of solid cancers are dysregulated in 1 of 3 ways:
by mutation, gene overexpression, or protein fusion.49
All three relevant mechanisms of kinase dysregulation
have been identified in glioblastoma, for example,
mutation of PIK3CA lipid kinase,50 overexpression of
the AURKA gene,51 and fusion of FIG to ROS kinase.52
Details on kinase involvement in glioblastoma can be
found in dedicated reviews.9,10,14,53,54 The protein
kinase gene family consists of 518 members.55 The
status of the vast majority of these kinases remains to be
determined in glioblastoma, and it is unclear which
kinases are best for targeting with small molecule inhibi-
tors. Therefore, it may prove worthwhile to evaluate
kinase targets other than those currently utilized for
small molecule inhibition in glioblastoma.56
Another fundamental question, if glioblastoma turns
out to be kinase driven, is which strategy is best for
kinase inhibition. For example, one of the more favor-
able responses in the clinical studies reviewed here has
been observed using the FLT1/KDR inhibitor cedira-
nib.17 A strategy alternative for inhibition of kinase sig-
naling other than using a small-molecule inhibitor is
binding of the ligand of receptor tyrosine kinases with
monoclonal antibodies. This strategy has recently been
shown to hold promise as a cancer therapy for glioblas-
toma.57–59
In conclusion, this review of published clinical studies
demonstrates small-molecule kinase inhibitors for adult
patients with glioblastoma to be not effective enough yet
to warrant a change in clinical practice, whereas the
evaluated drug targets have been generally limited to
EGFR, mTOR, KDR, FLT1, PKCb, and PDGFR.
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